A Study of Hospital-at-Home for People Receiving Tarlatamab
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMemorial Sloan Kettering Cancer Center
About this trial
The purpose of this study is to find out whether a Hospital-at-Home (HaH) program is a more efficient way to monitor people's health after receiving tarlatamab than monitoring in the hospital (inpatient).
Eligibility criteria
Qualifiers
Diagnosis of extensive stage small cell lung carcinoma (ES-SCLC)
Treatment plan of commercially available tarlatamab monotherapy as standard of care
Patients must be 18 years of age or older
Eastern Cooperative Oncology Group (ECOG) performance status <2
Disqualifiers
Patients with a documented active infection prior to starting tarlatamab. This includes grade 3 or higher viral, bacterial, or fungal infection.
Patients with baseline dementia or cognitive barriers
Uncontrolled arrhythmias
Caregiver deemed inappropriate by treating physician
Trial design
Treatments tested in this trial
- Hospital-at-Home/HAH
Treatment groups
70 Participants
are divided into 2 treatment groupsLocations
7Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)07920, Basking RidgeNew Jersey, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)07748, MiddletownNew Jersey, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)07645, MontvaleNew Jersey, United States
Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities)11725, CommackNew York, United States
Sponsors and collaborators
Memorial Sloan Kettering Cancer Center
Lead sponsor
Source ClinicalTrials.gov